Adial Pharmaceuticals, Inc.
ADIL
$1.97
$0.147.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.18M | 5.12M | 5.06M | 5.18M | 5.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.80M | 7.85M | 8.30M | 8.71M | 8.28M |
| Operating Income | -7.80M | -7.85M | -8.30M | -8.71M | -8.28M |
| Income Before Tax | -7.98M | -8.05M | -8.45M | -8.95M | -13.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.98 | -8.05 | -8.45 | -8.95 | -13.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.98M | -8.05M | -8.45M | -8.95M | -13.20M |
| EBIT | -7.80M | -7.85M | -8.30M | -8.71M | -8.28M |
| EBITDA | -7.80M | -7.85M | -8.30M | -8.71M | -8.28M |
| EPS Basic | -16.98 | -23.22 | -30.59 | -40.67 | -86.97 |
| Normalized Basic EPS | -10.61 | -14.51 | -19.12 | -25.42 | -54.35 |
| EPS Diluted | -16.98 | -23.22 | -30.59 | -40.67 | -86.97 |
| Normalized Diluted EPS | -10.61 | -14.51 | -19.12 | -25.42 | -54.35 |
| Average Basic Shares Outstanding | 2.67M | 1.83M | 1.18M | 918.90K | 775.50K |
| Average Diluted Shares Outstanding | 2.67M | 1.83M | 1.18M | 918.90K | 775.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |